Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14576MR)

This product GTTS-WQ14576MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14576MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5252MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ14290MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ6653MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ8080MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ100MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 1121B
GTTS-WQ12151MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-004
GTTS-WQ2676MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ2247MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW